单管PCR-Pyrosequencing快速检测华法林代谢酶基因多态性方法的建立

文章旨在建立一种单管、快速及高通量的华法林药物代谢酶相关基因多态性的检测方法。通过抽取人外周血DNA,应用带有生物素标记的扩增引物,经PCR扩增并制备焦磷酸测序单链模板,于PyroMark ID焦磷酸测序仪上进行焦磷酸测序,以Sanger测序法测序结果为对照,观察分析的准确性。结果显示,华法林药物代谢酶的3个相关基因多态性(CYP2C9*2、CYP2C9*3、VKORC1(-1693))于单管中可被同时检测,一次可获得96份DNA的华法林药物代谢相关多态性位点检测结果。经与Sanger测序方法比较,符合率为100%。结果表明本方法可准确、高通量、快速检测华法林药物代谢酶相关基因多态性,与单管检测一个位点的焦磷酸测序方法相比,能有效降低检测成本,节省检测时间。该方法在个性化医疗上有较大的推广应用价值,也可以将该平台运用于其他疾病相关基因多态性检测。     

30个枣树种质资源遗传多样性的ISSR分析

取30个枣树品种进行ISSR分子标记分析,其扩增条带分别进行琼脂糖和聚丙烯酰胺凝胶电泳检测,以期获得不同产地品种之间的遗传多态性。从100条选择扩增的ISSR引物中筛选出17条扩增清晰、重复性和稳定性好的引物,选取其中8条扩增条带多态性强的引物进行遗传聚类分析。结果表明：（1）1％琼脂糖凝胶电泳和5％聚丙烯酰胺凝胶电泳检测扩增总条带数分别为72和127条,其中多态性条带分别为51条和113条,多态性条带比率（PPB）分别为70．8％和88．9％。（2）基于UPGMA软件对30个品种的遗传差异性分析表明,8个ISSR引物可以将枣树品种之间遗传差异明显区分开来。两种电泳检测方法相比较,聚丙烯酰胺凝胶电泳检测可获得较为精细的枣树品种间遗传图谱。其遗传相似系数范围在0．56～1．00之间,以0．62为最低遗传相似系数,可将30个枣树品种分成3个大类,6个亚类,为进一步研究枣树品种间分类、起源进化关系和分子辅助育种奠定基础。     

基于 DArT 标记的三疣梭子蟹地理种群遗传多样性分析

三疣梭子蟹是中国重要的水产养殖动物。目前,其养殖业的蟹苗主要还是依靠野生资源,但种质（生长速度、肌肉品质和抗病性）退化现象严重,因此迫切需要了解个体、种群和物种遗传多样性。报道了一种检测三疣梭子蟹多样性芯片技术（diversityarraystechnology,DART）。DArT技术采用芯片可同时检测数百个基因座,即使没有基因组DNA序列信息也可以分析遗传多态性。采用了风tL／TaqI复杂性降低方法,多态性效率为12．5％。利用多样性芯片杂交获得313个DArT标记。这些DArT标记用于点制多态性富集芯片,DArT标记具有较高的多态性信息含量（polymorphisminformationcontent,PIC）。最后根据0／1矩阵获得UPGMA系统进化树,结果表明样品间的遗传多样性与文献报道一致。芯片质量检测中包括赋值重复性为99．1％,同一样品不同个体间的差异不显著,其差异介于0．7％～1．6％。研究表明,DArT技术具有高通量和低成本的显著特点,该技术可为三疣梭子蟹资源保护和良种选育提供支持。     

SSR标记在毛木耳种质资源遗传多样性研究中的应用

本研究利用基于毛木耳全基因组开发的SSR标记对27份毛木耳菌株（野生14株、栽培13株）的遗传多样性进行分析。首先随机选取3个菌株（2个野生菌株、1个栽培菌株）的DNA为模板,从144对SSR引物中筛选出扩增条带清晰、稳定性强、多态性丰富的引物24对。24对SSR引物共检测到116个多态性SSR片段,每对引物的多态性片段有3-7个,引物平均检测效率为4.83个,Shannon’s遗传多样性指数范围是0.866-1.885,多态性位点比率100%。供试菌株遗传相似系数范围是0.618-0.971,说明毛木耳种质资源具有丰富的遗传多样性。野生菌株与栽培菌株间平均遗传相似系数分别为0.746、0.779,说明毛木耳野生菌株遗传多样性更为丰富。经聚类分析,在遗传相似系数为0.680时,可将供试菌株分为无色（白色）类群Ⅰ和有色（浅黄色到红褐色）类群Ⅱ。遗传相似系数为0.704时,可将供试菌株中栽培菌株和野生菌株明显区分（14株野生菌株均在类群Ⅱ-2中,13株栽培菌株分别在类群Ⅰ和Ⅱ-1中）。本研究表明基于全基因组的SSR标记能从分子水平上揭示各菌株间的遗传差异,丰富毛木耳遗传多样性的研究手段,并为进一步进行毛木耳的品种选育、遗传学研究等提供有力手段。     

辣椒优良自交系间遗传差异的分子分析

作物自交系间遗传差异的分析与评价是杂种优势育种和杂交育种成功的基础。鲜食尖椒类(Capsicum an-nuumvar.longum)品种是我国辣椒生产的主要品种类型之一。针对我国鲜食尖椒的育种目标,以国内外10份尖椒优良自交系为材料,利用相关序列扩增多态性(SRAP)和简单序列重复(SSR)标记技术对其进行了遗传差异分析。结果显示:SRAP技术具有较高的位点和多态性检测能力,平均每次检测的位点数和多态性位点数分别为34个和10个,是SSR的10倍和5倍;辣椒自交系间基于SRAP标记的遗传距离和基于SSR标记的遗传距离之间的相关程度较低(r=0.144);基于SRAP标记和SSR标记联合数据计算的遗传距离,10个尖椒自交系被分为3大类,这种分类结果与辣椒杂种优势育种实践相一致。本研究结果表明,SRAP具有较高的遗传分析效力;基于不同分子标记遗传分析结果的差异与标记间共享位点的多少有关;10个尖椒自交系的分类结果可用于指导育种实践。     

H-FABP、MC4R、ADD1基因多态性在3个猪群中分布及其与肌内脂肪和背膘的相关研究

具有不同遗传特性的猪种具有不同的肉质性状。尤其是地方品种和引进品种间在肉质性状存在极大的差异。在已有的研究中H-FABP,MC4R,ADD1基因同肌内脂肪或背膘相关。利用梅山猪、苏太猪和杜×长×大猪为试验动物,研究上述3个基因的多态性分布和多态性同肌内脂肪和背膘的相关性。结果表明：3个基因的多态性分布在不同猪种间存在极显著的差异,这种差异可能是肌内脂肪（IMF）或背膘（BF）不同的主要原因之一。连锁分析表明：H-FABP和ADD1基因多态性同IMF有显著的相关,但是同BF没有显著的相关;MC4R基因的多态性同IMF和BF都有显著相关性。说明：H-FABP和ADD1基因多态性有可能应用到提高IMF,同时不影响BF的育种实践中。      

苏姜猪OLR1基因多态性及其与肉质性状的关联分析

探讨OLR1基因在苏姜猪群内的遗传多态性,以及该基因多态对苏姜猪猪肉质性状的影响。采用PCR-RFLP技术检测OLR1基因在苏姜猪试验群体中的PstⅠ酶切遗传多态性,运用单因素方差分析方法分析了该多态位点对苏姜猪肉质性状的影响。结果发现,苏姜猪试验群体OLR1基因内含子5区域内发现一个PstⅠ酶切多态性,检测到CC、CD和DD三种基因型,多态信息含量呈现中度多态性。CC型与DD型个体的肌肉失水率、大理石纹间的差异达到显著水平(P<0.05),CD型个体用色差仪测得的b值显著高于DD型(P<0.05)。因此,检测到的OLR1基因PCR-RFLP-PstⅠ多态性与大理石纹等肉质性状存在着显著的相关关系,可以作为肉质性状候选基因在苏姜猪的持续选育中加以应用。     

羊肚菌不同单孢及不同萌发孔菌丝间的遗传多样性

本研究对来自不同单孢和不同萌发孔菌丝的166份羊肚菌菌株进行形态研究、交配型基因检测、基于ISSR的遗传多样性分析和菌株杂交选育。结果表明,来自不同单孢及其不同萌发孔菌丝培养的菌株间均存在不同程度的形态和遗传差异。4条ISSR引物共扩增出条带清晰的22条多态性谱带,多态性比率为88%。基于遗传相似性系数（GS）、不加权成对群算术平均法（UPGMA）构建的系统树,可将供试菌株分为梯棱羊肚菌Morchella importuna和六妹羊肚菌M. sextelata两大类群。聚类分析发现不同物种间的单孢菌株和单丝菌株的遗传差异显著;同一单孢不同萌发孔菌丝的菌株间存在较大的遗传分化,遗传多样性丰富。交配型基因检测证实羊肚菌是异宗结合型真菌,同一单孢的不同萌发孔菌丝体含相同的交配型基因（MAT 1-1-1或MAT 1-2-1）。遗传多样性结果表明：梯棱羊肚菌比六妹羊肚菌的遗传背景更广泛。此外,ISSR分子标记也表明仅依靠菌丝和菌核的形态特征并不能准确衡量羊肚菌菌株间的亲缘关系。研究羊肚菌单孢菌株、单丝菌株间的形态和遗传特征,将为羊肚菌优质菌种的精准选育提供理论参考。     

基因多态性与药物的效能

长期以来,人们就认识到不同的个体对同一种药物的反应存在着差异,这直接影响着药物的疗效和不良反应。本文从药物代谢基因、药物受体相关基因、药物转运基因和疾病通路基因等方面论述了基因多态性与药物效能的关系。有关这方面的研究,为开发安全、有效的药物,指导临床个性化合理用药,减少毒、副作用,提供了新的思路。     

MDR1基因多态性及其临床相关性研究进展

体内外研究证明,人体中P—gP在药物的吸收、分布、代谢和排泄（ADME）过程中发挥了非常重要的作用。多药耐药基因MDR1（ABCB1）是P-gP的编码基因。药物基因组学和遗传药理学研究发现在不同个体中MDR1基因多态性与P—gP表达和功能的改变密切相关,而且这些多态位点存在基因型分布和等位基因频率的种族差异性。近几年,已陆续发现在MDR1基因中有50处单核苷酸多态性（SNPs）和3处插入与缺失多态性。随后,大量文献报道某些位点的SNPs如C3435T会使个体患病的易感性增加。因此人们相信,深入研究MDR1基因多态性与P—gP的生理和生化方面的相关性将对个体医疗有着非常深远的意义。文章总结了国外最新的研究进展并结合本实验室的工作着重讨论了4个方面：1）P—gP对药代动力学性质的影响：2）MDR1基因多态性及其对遗传药理学性质的影响;3）MDR1^C3435T的单核苷酸多态性与P-gP表达和功能之间的相关性：4）MDR1基因多态性与人类某些疾病之间的相关性。     

Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase

1. Pharmacogenomics is the study of the role of inheritance in variation in the drug response phenotype-a phenotype that can vary from adverse drug reactions at one end of the spectrum to lack of therapeutic efficacy at the other. 2. The thiopurine S-methyltransferase (TPMT) genetic polymorphism represents one of the best characterized and most clinically relevant examples of pharmacogenomics. This polymorphism has also served as a valuable "model system" for studies of the ways in which variation in DNA sequence might influence function. 3. The discovery and characterization of the TPMT polymorphism grew directly out of pharmacogenomic studies of catechol O-methyltransferase (COMT), an enzyme discovered by Julius (Julie) Axelrod and his coworkers. 4. This review will outline the process by which common, functionally significant genetic polymorphisms for both COMT and TPMT were discovered and will use these two methyltransferase enzymes to illustrate general principles of pharmacogenomic research-both basic mechanistic and clinical translational research-principles that have been applied to a series of genes encoding methyltransferase enzymes.     

Pharmacogenomics: Catechol O-Methyltransferase to Thiopurine S-Methyltransferase

1. Pharmacogenomics is the study of the role of inheritance in variation in the drug response phenotype—a phenotype that can vary from adverse drug reactions at one end of the spectrum to lack of therapeutic efficacy at the other.2. The thiopurine S-methyltransferase (TPMT) genetic polymorphism represents one of the best characterized and most clinically relevant examples of pharmacogenomics. This polymorphism has also served as a valuable “model system” for studies of the ways in which variation in DNA sequence might influence function.3. The discovery and characterization of the TPMT polymorphism grew directly out of pharmacogenomic studies of catechol O-methyltransferase (COMT), an enzyme discovered by Julius (Julie) Axelrod and his coworkers.4. This review will outline the process by which common, functionally significant genetic polymorphisms for both COMT and TPMT were discovered and will use these two methyltransferase enzymes to illustrate general principles of pharmacogenomic research—both basic mechanistic and clinical translational research—principles that have been applied to a series of genes encoding methyltransferase enzymes.     

The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era

Pharmacogenomics is emerging as a popular type of study for human genetics in recent years. This is primarily due to the many success stories and high potential for translation to clinical practice. In this review, the strengths and limitations of pharmacogenomics are discussed as well as the primary epidemiologic, clinical trial, and in vitro study designs implemented. A brief discussion of molecular and analytic approaches will be reviewed. Finally, several examples of bench-to-bedside clinical implementations of pharmacogenetic traits will be described. Pharmacogenomics continues to grow in popularity because of the important genetic associations identified that drive the possibility of precision medicine.     

小细胞肺癌患者铂类化疗 所致周围神经毒性与SNP相关性

小细胞肺癌(SCLC)患者的治疗正在发生改变,但含铂双药联合化疗仍然是大多数SCLC患者的治疗基础。SCLC患者在接受化学治疗同时,还需忍受药物毒性引起的周围神经毒性(peripheral neurotoxicity,PN)等相关毒副作用。周围神经毒性主要表现为刺痛、麻木、虚弱或灼痛,且呈剂量依赖性。药物基因组学现已发展为一种有效的研究方法,目前可以利用基因组学获得关于药物反应的个体间差异的相关遗传信息,从而避免周围神经毒性的发生,以达到精准治疗的目的。单核苷酸多态性(single nucleotide polymorphism,SNP)定义为在基因组水平上由于单个核苷酸的变异而导致的DNA序列多态性。人类可遗传变异中最多的就是SNP,甚至在已知的所有多态性中90%以上都是单核苷酸变异。本文就小细胞肺癌患者铂类药物引起的周围神经毒性与相关GSTP1和GSTM1基因、ERCC1基因、ABCC2和ABCC4基因、SCNAs基因、CYP2C8基因、AGXT基因的SNP之间的关系作一简要综述。     

Cancer pharmacogenomics: current and future applications

Heterogeneity in patient response to chemotherapy is consistently observed across patient populations. Pharmacogenomics is the study of inherited differences in interindividual drug disposition and effects, with the goal of selecting the optimal drug therapy and dosage for each patient. Pharmacogenomics is especially important for oncology, as severe systemic toxicity and unpredictable efficacy are hallmarks of cancer therapies. In addition, genetic polymorphisms in drug metabolizing enzymes and other molecules are responsible for much of the interindividual differences in the efficacy and toxicity of many chemotherapy agents. This review will discuss clinically relevant examples of gene polymorphisms that influence the outcome of cancer therapy, and whole-genome expression studies using microarray technology that have shown tremendous potential for benefiting cancer pharmacogenomics. The power and utility of the mouse as an experimental system for pharmacogenomic discovery will also be discussed in the context of cancer therapy.     

Pharmacogenomics of pediatric asthma

CONTEXT:

Asthma is a complex disease with multiple genetic and environmental factors contributing to it. A component of this complexity is a highly variable response to pharmacological therapy. Pharmacogenomics is the study of the role of genetic determinants in the variable response to therapy. A number of examples of possible pharmacogenomic approaches that may prove of value in the management of asthma are discussed below.

EVIDENCE ACQUISITION:

A search of PubMed, Google scholar, E-Medicine, BMJ and Mbase was done using the key words “pharmacogenomics of asthma”, “pharmacogenomics of β-agonist, glucocorticoids, leukotriene modifiers, theophylline, muscarinic antagonists in asthma”.

RESULTS:

Presently, there are limited examples of gene polymorphism that can influence response to asthma therapy. Polymorphisms that alter response to asthma therapy include Arg16Gly, Gln27Glu, Thr164Ile for β-agonist receptor, polymorphism of glucocorticoid receptor gene, CRHR1 variants and polymorphism of LTC4S, ALOX5. Polymorphic variants of muscarinic receptors, PDE4 and CYP450 gene variants.

CONCLUSION:

It was concluded that genetic variation can improve the response to asthma therapy. However, no gene polymorphism has been associated with consistent results in different populations. Therefore, asthma pharmacogenomic studies in different populations with a large number of subjects are required to make possible tailoring the asthma therapy according to the genetic characteristic of individual patient.     

药物基因组学——个性化药物的开发

药物基因组学是研究药物反应的遗传机制及药物反应的个体差异性。本文详细讨论了药物基因组学的发展历史,种族,个体的遗传差异性对药物反应的影响;介绍了当前从事药物基因组学开发研究的公司情况及医药管理机构关于药物基因组学的指导性文件;本文也论述了遗传多态性及疾病诊断和疾病相关基因鉴定的最新研究进展 。     

Genes as Cues of Relatedness and Social Evolution in Heterogeneous Environments

There are many situations where relatives interact while at the same time there is genetic polymorphism in traits influencing survival and reproduction. Examples include cheater-cooperator polymorphism and polymorphic microbial pathogens. Environmental heterogeneity, favoring different traits in nearby habitats, with dispersal between them, is one general reason to expect polymorphism. Currently, there is no formal framework of social evolution that encompasses genetic polymorphism. We develop such a framework, thus integrating theories of social evolution into the evolutionary ecology of heterogeneous environments. We allow for adaptively maintained genetic polymorphism by applying the concept of genetic cues. We analyze a model of social evolution in a two-habitat situation with limited dispersal between habitats, in which the average relatedness at the time of helping and other benefits of helping can differ between habitats. An important result from the analysis is that alleles at a polymorphic locus play the role of genetic cues, in the sense that the presence of a cue allele contains statistical information for an organism about its current environment, including information about relatedness. We show that epistatic modifiers of the cue polymorphism can evolve to make optimal use of the information in the genetic cue, in analogy with a Bayesian decision maker. Another important result is that the genetic linkage between a cue locus and modifier loci influences the evolutionary interest of modifiers, with tighter linkage leading to greater divergence between social traits induced by different cue alleles, and this can be understood in terms of genetic conflict.     

Spatiotemporal environmental heterogeneity and the maintenance of the tailspot polymorphism in the variable platyfish (Xiphophorus variatus)

Genetic variation is critical for adaptive evolution. Despite its importance, there is still limited evidence in support of some prominent theoretical models explaining the maintenance of genetic polymorphism within populations. We examined 84 populations of Xiphophorus variatus, a livebearing fish with a genetic polymorphism associated with physiological performance, to test: (1) whether niche differentiation explains broad‐scale maintenance of polymorphism, (2) whether polymorphism is maintained among populations by local adaptation and migration, or (3) whether heterogeneity in explicit environmental variables could be linked to levels of polymorphism within populations. We found no evidence of climatic niche differentiation that could generate or maintain broad geographic variation in polymorphism. Subsequently, hierarchical partitioning of genetic richness and partial mantel tests revealed that 76% of the observed genetic richness was partitioned within populations with no effect of geographic distance on polymorphism. These results strongly suggest a lack of migration‐selection balance in the maintenance of polymorphism, and model selection confirmed a significant relationship between environmental heterogeneity and genetic richness within populations. Few studies have demonstrated such effects at this scale, and additional studies in other taxa should examine the generality of gene‐by‐environment interactions across populations to better understand the dynamics and scale of balancing selection.     

Pharmacogenomics of osteoporosis: opportunities and challenges

The genetics of osteoporosis can be considered in two broad areas: disease susceptibility and drug activity. While the former has been studied, the latter is still largely untouched. Pharmacogenomics is the utilization of genetic information to predict outcome of drug treatment, with respect to both beneficial and adverse effects. The pharmacotherapy of osteoporosis is characterized by variability in therapeutic response with limited prediction of response on a patient-by-patient basis. This is particularly problematic in a clinical situation where therapy is typically required for several years before outcomes can be evaluated for an individual. Thus, the emerging field of pharmacogenomics holds great potential for refining and optimising pharmacological treatment of osteoporosis. Key components for future development of the pharmacogenomics of osteoporosis should include improved understanding of mechanisms of drug action, identification of candidate genes and their variants and expansion of clinical trials to include genetic profiling. This approach could provide clinicians and scientists with powerful tools to dissect novel molecular pathways involved in osteoporosis and to identify new drug targets. The iterative combination of innovative genomics with classical endocrinological approaches in osteoporosis research can be examined as a model of biological research and innovate therapeutical approaches in a continuing interaction between clinical science and basic research.